Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor

Oncology (Switzerland)

Volumn 90, Issue 2, 2016, Pages 112-117

  Wada, Noriko ^a   Kurokawa, Yukinori ^a   Takahashi, Tsuyoshi ^a   Hamakawa, Takuya ^a   Hirota, Seiichi ^b   Naka, Tetsuji ^c   Miyazaki, Yasuhiro ^a   Makino, Tomoki ^a   Yamasaki, Makoto ^a   Nakajima, Kiyokazu ^a   Takiguchi, Shuji ^a   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

C KIT mutation; Cell free DNA; Circulating tumor DNA; Gastrointestinal stromal tumor; Next generation sequencing

Indexed keywords

CIRCULATING TUMOR DNA; DNA; IMATINIB; SUNITINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; STEM CELL FACTOR RECEPTOR;

ADULT; ARTICLE; BLOOD; CANCER SURGERY; CASE REPORT; EXON; GASTRECTOMY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; MALE; MIDDLE AGED; ONCOGENE C KIT; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; TOTAL STOMACH RESECTION; TUMOR GROWTH; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENETICS; MUTATION;

ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; EXONS; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMATINIB MESYLATE; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84955615188     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000442948     Document Type: Article

References (21)

1. Corless CL, Barnett CM, Heinrich MC: Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011; 11: 865-878.
2. Takahashi T, Serada S, Ako M, Fujimoto M, Miyazaki Y, Nakatsuka R, Ikezoe T, Yokoyama A, Taguchi T, Shimada K, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Mori M, Doki Y, Naka T, Nishida T: New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis. Int J Cancer 2013; 133: 2737-2743.
3. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I: Progression-free survival in gastrointestinal stromal tumours with highdose imatinib: randomised trial. Lancet 2004; 364: 1127-1134.
4. Joensuu H, Hohenberger P, Corless CL: Gastrointestinal stromal tumour. Lancet 2013; 382: 973-983.
5. Yoshikawa K, Shimada M, Kurita N, Sato H, Iwata T, Morimoto S, Miyatani T, Kashihara H, Takasu C, Matsumoto N: The efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors. Surg Today 2013; 43: 1162-1167.
6. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
7. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schoffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 295-302.
8. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352-5359.
9. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, Thierauch KH, Zopf D: Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129: 245-255.
10. George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD: Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012; 30: 2401-2407.
11. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA Jr: Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14: 985-990.
12. Schwarzenbach H, Hoon DS, Pantel K: Cellfree nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-437.
13. Hamakawa T, Kukita Y, Kurokawa Y, Miyazaki Y, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Taniguchi K, Takiguchi S, Mori M, Doki Y, Kato K: Monitoring gastric cancer progression with circulating tumour DNA. Br J Cancer 2015; 112: 352-356.
14. Kukita Y, Uchida J, Oba S, Nishino K, Kumagai T, Taniguchi K, Okuyama T, Imamura F, Kato K: Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS One 2013; 8:e81468.
15. Nishida T, Kanda T, Nishitani A, Takahashi T, Nakajima K, Ishikawa T, Hirota S: Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci 2008; 99: 799-804.
16. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37: 646-650.
17. Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, Schwarzenbach H: Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. Int J Cancer 2010; 128: 2572-2580.
18. Spellman PT, Gray JW: Detecting cancer by monitoring circulating tumor DNA. Nat Med 2014; 20: 474-475.
19. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D: BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 2006; 3: 551-559.
20. Maier J, Lange T, Kerle I, Specht K, Bruegel M, Wickenhauser C, Jost P, Niederwieser D, Peschel C, Duyster J, von Bubnoff N: Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA. Clin Cancer Res 2013; 19: 4854-4867.
21. Kang G, Bae BN, Sohn BS, Pyo JS, Kang GH, Kim KM: Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor. Target Oncol 2015; 10: 597-601.